Windward Bio IPO: $175M Raise Puts Twice-Yearly Asthma Antibody in the Spotlight
Novo-backed Windward Bio raised $175M in its Nasdaq IPO, plus $50M from Sanofi, to fund WIN378, an anti-TSLP antibody aimed at twice-yearly dosing in asthma and COPD.
Tag: asthma
Read More